-
公开(公告)号：US11046683B2
公开(公告)日：2021-06-29
申请号：US16470196
申请日：2017-12-14
发明人： Craig W Lindsley , Joshua M. Wieting , Kevin M. McGowan , Jerod S. Denton , Kentaro Yashiro , Haruto Kurata , Yoko Sekioka , Takahiro Mori , Yuzo Iwaki
IPC分类号： C07D471/04 , C07D257/04 , A61K31/41 , A61K31/4245 , A61K31/4353 , A61K31/4439 , A61K31/5375 , C07C255/57 , C07C317/28 , C07D209/30 , C07D213/89 , C07D231/56 , C07D235/16 , C07D237/24 , C07D239/47 , C07D249/08 , C07D249/18 , C07D265/36 , C07D271/10 , C07D285/14 , C07D295/04 , C07D401/04 , C07D513/04
摘要： Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.
-
公开(公告)号：US11851428B2
公开(公告)日：2023-12-26
申请号：US17328814
申请日：2021-05-24
发明人： Craig W. Lindsley , Joshua M. Wieting , Kevin M. Mcgowan , Jerod S. Denton , Kentaro Yashiro , Haruto Kurata , Yoko Sekioka , Takahiro Mori , Yuzo Iwaki
IPC分类号： C07D213/36 , C07D231/12 , C07D249/08 , C07D401/04 , A61K31/454 , C07D471/04 , C07C255/57 , C07C317/28 , C07D209/30 , C07D213/89 , C07D231/56 , C07D235/16 , C07D237/24 , C07D239/47 , C07D249/18 , C07D257/04 , C07D265/36 , C07D271/10 , C07D285/14 , C07D295/04 , C07D513/04
CPC分类号： C07D471/04 , C07C255/57 , C07C317/28 , C07D209/30 , C07D213/89 , C07D231/56 , C07D235/16 , C07D237/24 , C07D239/47 , C07D249/08 , C07D249/18 , C07D257/04 , C07D265/36 , C07D271/10 , C07D285/14 , C07D295/04 , C07D401/04 , C07D513/04
摘要： Disclosed is a compound of formula (I):
wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.-
公开(公告)号：US10570093B2
公开(公告)日：2020-02-25
申请号：US16059270
申请日：2018-08-09
IPC分类号： C07D213/61 , A61K31/17 , A61K31/341 , A61K31/351 , A61K31/381 , A61K31/4045 , A61K31/417 , A61K31/422 , A61K31/4245 , A61K31/426 , A61K31/435 , A61K31/4545 , A61K31/4965 , A61K31/505 , C07D213/74 , C07D309/04 , C07C275/32 , C07C275/40 , C07D333/20 , C07D333/28 , C07D233/64 , C07D239/26 , C07D413/06 , C07D241/12 , C07C233/26 , C07C233/29 , C07D271/06 , C07D277/28 , C07D209/30 , C07D213/40 , C07D307/52
摘要： The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
-
公开(公告)号：US10519105B2
公开(公告)日：2019-12-31
申请号：US16095374
申请日：2017-04-21
发明人： Kentaro Yashiro , Masashi Kato , Tetsuji Saito , Takuya Okada , Daisuke Wakamatsu , Adam James Davenport , Christopher Charles Stimson
IPC分类号： C07C275/32 , C07C271/30 , A61P13/02 , A61K31/17 , A61K31/27 , A61K31/341 , A61K31/351 , A61K31/4045 , A61K31/42 , A61K31/426 , A61K31/44 , A61K31/4545 , A61K31/4965 , A61K31/505 , C07D213/74 , C07D309/04 , C07D239/26 , C07D241/12 , C07D261/08 , C07D277/28 , C07D209/14 , C07D213/40 , C07D213/64 , C07D307/52 , A61P13/10
摘要： An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).
-
公开(公告)号：US10676438B2
公开(公告)日：2020-06-09
申请号：US16059270
申请日：2018-08-09
IPC分类号： C07D213/61 , A61K31/17 , A61K31/341 , A61K31/351 , A61K31/381 , A61K31/4045 , A61K31/417 , A61K31/422 , A61K31/4245 , A61K31/426 , A61K31/435 , A61K31/4545 , A61K31/4965 , A61K31/505 , C07D213/74 , C07D309/04 , C07C275/32 , C07C275/40 , C07D333/20 , C07D333/28 , C07D413/06 , C07C233/26 , C07C233/29 , C07D209/30 , C07D213/40 , C07D233/64 , C07D239/26 , C07D241/12 , C07D271/06 , C07D277/28 , C07D307/52
摘要： The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
-
公开(公告)号：US20180346422A1
公开(公告)日：2018-12-06
申请号：US16059270
申请日：2018-08-09
IPC分类号： C07D213/61 , C07D307/52 , A61K31/17 , C07D213/40 , C07D209/30 , C07D277/28 , C07D271/06 , C07C233/29 , C07C233/26 , C07D241/12 , C07D413/06 , C07D239/26 , C07D233/64 , C07D333/28 , C07D333/20 , C07C275/40 , C07C275/32 , C07D309/04 , C07D213/74 , A61K31/505 , A61K31/4965 , A61K31/4545 , A61K31/435 , A61K31/426 , A61K31/4245 , A61K31/422 , A61K31/417 , A61K31/4045 , A61K31/381 , A61K31/351 , A61K31/341
摘要： The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
-
公开(公告)号：US09809544B2
公开(公告)日：2017-11-07
申请号：US15515243
申请日：2015-10-23
IPC分类号： C07D213/61
CPC分类号： C07D213/61 , A61K31/17 , A61K31/341 , A61K31/351 , A61K31/381 , A61K31/4045 , A61K31/417 , A61K31/422 , A61K31/4245 , A61K31/426 , A61K31/435 , A61K31/4545 , A61K31/4965 , A61K31/505 , C07C233/26 , C07C233/29 , C07C275/32 , C07C275/40 , C07D209/30 , C07D213/40 , C07D213/74 , C07D233/64 , C07D239/26 , C07D241/12 , C07D271/06 , C07D277/28 , C07D307/52 , C07D309/04 , C07D333/20 , C07D333/28 , C07D413/06
摘要： The present invention relates to a compound, 1-[(5-chloro-2-pyridinyl)methyl]-3-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}urea, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US10196358B2
公开(公告)日：2019-02-05
申请号：US15671428
申请日：2017-08-08
IPC分类号： C07D213/61 , A61K31/44 , A61K31/17 , A61K31/341 , A61K31/351 , A61K31/381 , A61K31/4045 , A61K31/417 , A61K31/422 , A61K31/4245 , A61K31/426 , A61K31/435 , A61K31/4545 , A61K31/4965 , A61K31/505 , C07D213/74 , C07D309/04 , C07C275/32 , C07C275/40 , C07D333/20 , C07D333/28 , C07D233/64 , C07D239/26 , C07D413/06 , C07D241/12 , C07C233/26 , C07C233/29 , C07D271/06 , C07D277/28 , C07D209/30 , C07D213/40 , C07D307/52
摘要： The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
-
公开(公告)号：US20170334855A1
公开(公告)日：2017-11-23
申请号：US15671428
申请日：2017-08-08
IPC分类号： C07D213/61
CPC分类号： C07D213/61 , A61K31/17 , A61K31/341 , A61K31/351 , A61K31/381 , A61K31/4045 , A61K31/417 , A61K31/422 , A61K31/4245 , A61K31/426 , A61K31/435 , A61K31/4545 , A61K31/4965 , A61K31/505 , C07C233/26 , C07C233/29 , C07C275/32 , C07C275/40 , C07D209/30 , C07D213/40 , C07D213/74 , C07D233/64 , C07D239/26 , C07D241/12 , C07D271/06 , C07D277/28 , C07D307/52 , C07D309/04 , C07D333/20 , C07D333/28 , C07D413/06
摘要： The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.023 秒)
